VISULAS 690s by Zeiss: Laser Precision for AMD Treatment
The VISULAS 690s by Zeiss is a therapeutic laser system specifically designed to meet the stringent requirements of age-related macular degeneration (AMD) treatment through photodynamic therapy (PDT). Leveraging the synergy between 689 nm laser technology and the photosensitizer Visudyne™, this system enables selective targeting of choroidal neovascularization while preserving healthy retinal tissue. Unlike conventional photocoagulation methods, the VISULAS 690s does not damage the photoreceptor layer, helping to maintain patients’ visual acuity.
The device stands out for its ergonomic design tailored to practitioners and its emphasis on patient safety. The VISULINK® PDT/U adapter, compatible with a wide range of slit lamps (Zeiss SL 115, SL 120, SL 130, 20 SL, 30 SL, and Haag-Streit 900® BM/BQ), offers high integration flexibility for clinics and private practices. The system delivers a uniform and stable laser beam, with integrated power monitoring via three independent diodes and a fiber deterioration sensor, ensuring safe and controlled treatment sessions.
Designed for portability, the VISULAS 690s features a compact footprint and a durable transport case, making it ideal for mobile or multi-site clinical environments. Its integrated software provides advanced configuration options such as assisted spot size selection, contact lens identification by name, exposure control timer, and an acoustic signal confirming successful treatment delivery.
The system also fits seamlessly into a comprehensive visual treatment workflow, integrating with other Zeiss technologies such as the FF 450 fundus camera, VISUPAC documentation system, and OCT for detailed retinal tissue evaluation. CE certified since 1998, the VISULAS 690s was the laser platform used in Visudyne™ Phase III clinical trials, attesting to its clinical reliability and proven efficacy.
Combining safety, user-friendliness, hardware compatibility, and therapeutic precision, the VISULAS 690s is a strategic choice for ophthalmologists seeking a focused and clinically sound approach to AMD management via photodynamic therapy.
